首页 | 本学科首页   官方微博 | 高级检索  
     


Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status
Authors:Po-Hong Liu  Yun-Hsuan Lee  Chia-Yang Hsu  Cheng-Yuan Hsia  Yi-Hsiang Huang  Yi-You Chiou  Han-Chieh Lin  Teh-Ia Huo
Affiliation:1. Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
4. Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan
7. Department of Biostatistics, UCLA, Los Angeles, CA, USA
5. Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
2. Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan
6. Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan
3. Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan
Abstract:

Background and Aims

Performance status is tightly linked with survival in patients with hepatocellular carcinoma (HCC). We investigated the impact of performance status on HCC patients beyond the Milan criteria receiving surgical resection (SR) or transarterial chemoembolization (TACE).

Methods

A total of 909 patients with HCC beyond the Milan criteria were retrospectively analyzed by using propensity score analysis.

Results

The baseline characteristics were similar between the SR and TACE group for patients with performance status 0 in the propensity model. More patients in the TACE group with performance status ≥1 had Child-Turcotte-Pugh class A compared to the SR group (p?=?0.044) in the propensity model. SR provided significantly better long-term overall survival than TACE in patients selected in the propensity model regardless of performance status (both p?TACE was associated with 2.279-fold and 3.066-fold increased risk of mortality in performance status 0 and performance status ≥1 in the propensity model (95 % confidence interval, 1.476–3.591 and 1.570–5.989), respectively.

Conclusions

For either performance status 0 or ≥1 HCC patients beyond the Milan criteria, SR provides significantly better long-term survival than TACE. SR should be considered a priority treatment in these patients independent of performance status.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号